In PIONEER, Rybelsus produced about 4% average body-weight loss over 26 weeks. That is a trial average; individual results vary widely and depend on staying on treatment.
What Rybelsus is approved for
Blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk of them. It is not approved for weight loss.
Rybelsus weight-loss results
Rybelsus produced 4% mean body-weight reduction in the PIONEER pivotal trial at 26 weeks. That figure is a mean: within the same trial some people lost far more and a minority lost little, so read it as the middle of a wide spread rather than a target.
How effective is Rybelsus?
Mean body-weight change at 26 weeks in the PIONEER trial. Source: FDA prescribing information.
Vs placebo
+3.0 pts
Modest signal — discuss with prescriber
Vs GLP-1 class ceiling
18% of ceiling
Lower-tier — newer drugs available
Individual results vary. Trial participants also received lifestyle counseling. Full disclaimer.
Expected weight-loss curve
Mean body-weight change across 26 weeks on Rybelsus from the PIONEER trial. Curve smoothed from published endpoints; individual results vary significantly.
Trial participants also received lifestyle counseling. Real-world results depend on dose adherence, side-effect tolerance, and lifestyle factors.
Why results vary, what happens after stopping, and how GLP-1 medicines compare with other approaches are covered once for the whole class in GLP-1 weight-loss results. Side effects that make people stop early are on the Rybelsus side effects page.
FAQ about Rybelsus for weight loss
Is Rybelsus FDA-approved for weight loss?
No. The label's approved uses: blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk of them. It is not approved for weight loss.
Educational only, not medical advice. Full medical disclaimer.